CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.
CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $5CF PharmTechM in Series F financing following its US $9CF PharmTechM Series E financing in January of 2CF PharmTech2CF PharmTech, in total, successfully completing an equity investment deal of nearly US $14CF PharmTechM within six months. The investors participated in the Series F financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment. Its existing investors including Passion Capital and Yuanming Capital also participated. CEC Capital served as CF PharmTech's exclusive financial advisor for both Series E and F financing.
There are nearly 300 million people suffering from asthma, chronic obstructive pulmonary disease (COPD) or rhinitis in China. The occurrence of these chronic diseases continues to rise. The State Council's Opinions on the Implementation of Healthy China Actions issued by the State Council in July 2019 defined COPD in China as a major chronic disease that seriously affects quality of life, along with cancers, cardiovascular disease and diabetes. With this new round of funding, CF Pharmtech is more poised than ever to provide respiratory disease treatments for China and global market.
About CF PharmTech:
CF PharmTech is a fully integrated specialty pharmaceutical company dedicated to providing affordable and high-quality respiratory drugs globally. Managed by a high caliber team with extensive experience in the industry, the company focuses on the development of drugs for the treatment of respiratory diseases in its state-of-the-art facilities. Learn more about CF PharmTech, visit www.cfpharmtech.com.
Photo - https://photos.prnasia.com/prnh/20200701/2846325-1
Caption: CF PharmTech’s manufacturing facility
ข่าวCF PharmTech+o:prncnวันนี้
ChuanQi IP, "MIR2M: The Grandmaster" Release Airdrop Event in Progress
3rd Mobile Title Based on "The Legend of Mir 2" Universe Features Various Contents such as PvP Battles, Boss Dungeons, Guild System Commemorative Events Include Mission Completion, Gameplay Review Video Production ChuanQi IP, a subsidiary of WEMADE (CEO: Henry Chang), has officially released the blockchain-based idle martial arts RPG, "MIR2M: The Grandmaster," today (2nd). "MIR2M: The Grandmaster" is the third title in the MIR2M series. Based on "The Legend of Mir 2" universe, it tells the story
ฉวนฉี ไอพี จัดกิจกรรมแอร์ดรอปฉลองการเปิดตัวเกม "MIR2M: The Grandmaster"
—
เกมมือถือเกมที่ 3 ในจักรวาล "The Legend of Mir 2" อัดแน่นด้วยคอนเทนต์หลากหลาย ทั...
CF PharmTech จับมือ Chengdu Shangyi เปิดตัว "โปรแกรมฟื้นฟูสุขภาพที่บ้านสำหรับผู้ป่วยโควิด-19 ที่รักษาหายแล้ว" พร้อมปล่อยแอป "R Plus Health" ให้ใช้ฟรีทั่วโลก
CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global Release of the "R Plus Health" Free App
CF PharmTech ปิดระดมทุน Series F วงเงิน 50 ล้านดอลลาร์ เร่งผลิตยาสูดพ่นออกสู่ตลาด
—
CF PharmTech, Inc. ประกาศว่า บริษัทได้รับเงินลงทุน 50 ล้านดอลลาร์สหรัฐ...
CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.
—
CF PharmTech, Inc. ("CF PharmTech...
CF PharmTech ปิดระดมทุนวงเงิน 90 ล้านดอลลาร์สหรัฐ มุ่งพัฒนายารักษาโรคระบบทางเดินหายใจ
—
CF PharmTech, Inc. บริษัทเภสัชกรรมที่มีวิสัยทัศน์เพื่อพัฒนาและผลิต...
CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs
—
CF PharmTech, Inc., a pharmaceutical company wi...